Nearly two-thirds of American adults who start a GLP-1 receptor agonist for weight management without having diabetes stop taking it within a year. That figure, 64.8 percent, comes from an analysis of more than 125,000 patients published in JAMA Network Open, and it lands like a splash of cold water on one of the most celebrated stories in modern medicine. The newest generation of anti-obesity medications has produced weight-loss results in clinical trials that clinicians once thought impossible without surgery. Yet in the real world, the majority of people who begin these therapies never reach the durations at which those results were achieved.
Adherence, the unglamorous business of actually staying on a therapy as prescribed, has quietly become the single most important variable separating the outcomes seen in randomized trials from the outcomes seen in pharmacy-claims databases. The medications themselves have not changed between the trial site and the neighborhood pharmacy. What changes is everything around them: cost, coverage, side-effect management, supply, and the presence or absence of a clinician who is paying attention.
Understanding why so many patients fall off these therapies, and what the data says about who stays on them, has become an urgent question for payers, prescribers, and the millions of adults now weighing whether to start.
An Adoption Boom Colliding With a Persistence Problem
The scale of uptake is historic. A KFF Health Tracking Poll found that roughly one in eight American adults reported having taken a GLP-1 medication at some point, a remarkable penetration for a drug class that entered mainstream weight-management use only a few years ago. Demand has repeatedly outrun supply, and prescribing has expanded from endocrinology clinics into primary care and telehealth at a pace few drug categories have ever matched.
Persistence has not kept up with enthusiasm. A pharmacy-claims analysis from Blue Health Intelligence reported that fewer than half of patients prescribed semaglutide for weight management remained on the prescription for twelve weeks or more, a window shorter than the time most patients need to complete the gradual ramp-up phase of therapy. Longer horizons look thinner still: research presented by Prime Therapeutics found that only about 14 percent of patients who started these medications were still on therapy at the end of two years.
There is genuine improvement inside those numbers. A study in the Journal of Managed Care & Specialty Pharmacy found that one-year persistence among commercially insured adults without diabetes nearly doubled from 33 percent among those who started in 2021, an improvement researchers attributed to easing supply shortages, better side-effect management, refined ramp-up protocols, and the spread of structured care-management programs. The trajectory is encouraging. The absolute level is still far below what the underlying science assumes.
The Gap Between Trial Results and Real-World Outcomes
Why does adherence matter so much? Because the headline weight-loss figures from clinical trials were generated by participants who, by design, stayed on therapy for a year or more with intensive clinical support. Real-world patients rarely replicate those conditions.
Cleveland Clinic researchers, publishing in the journal Obesity, quantified the consequence. Analyzing electronic health records from patients seen between 2021 and 2023, they found that semaglutide and tirzepatide produced considerably smaller weight loss in everyday practice than in the randomized trials that made the drugs famous. The reasons were not pharmacological. More than 20 percent of patients discontinued within three months, another 32 percent discontinued between three and twelve months, and over 80 percent were maintained on lower doses than trial protocols used. The drug in the real-world syringe was identical to the drug in the trial syringe; the persistence surrounding it was not.
This distinction matters for anyone forming expectations. A patient who reads trial results and then uses the medication for ten weeks before stopping is, statistically speaking, running a different experiment entirely. Obesity researchers increasingly describe these medications as long-term therapies for a chronic condition, closer in kind to blood-pressure or cholesterol management than to a short course of intervention. Viewed through that lens, a therapy that most patients abandon within a year has a delivery problem, not an efficacy problem.
Why Patients Stop
The drivers of discontinuation are well documented, and most of them have little to do with the medications failing to work.
Cost and Coverage
Across nearly every real-world dataset, cost and insurance barriers emerge as the dominant reason patients stop. List prices for the leading anti-obesity medications run to hundreds of dollars per month, employer coverage remains inconsistent, and prior-authorization requirements can interrupt therapy even for covered patients. The Institute for Clinical and Economic Review has flagged affordability as the central obstacle standing between these medications and the population that could benefit from them. When a refill becomes a monthly financial negotiation, persistence suffers.
Side Effects Without Support
Gastrointestinal side effects such as nausea are common, particularly during the early ramp-up period, and they are manageable for many patients with clinical guidance on pacing, diet, and timing. Without that guidance, they become exit ramps. A study examining reasons for discontinuation of semaglutide and tirzepatide in clinical practice found that roughly 30 percent of patients who stopped did so because of adverse effects. Many of those departures may have been avoidable with earlier clinical contact, since slowing the ramp-up or adjusting supportive care can often carry patients through the adjustment window.
Access and Supply Disruptions
The shortage years scrambled continuity for hundreds of thousands of patients. Pharmacy stockouts forced gaps in therapy, and gaps have a way of becoming endings. The JMCP persistence research pointed to the resolution of supply-chain problems as one of the main reasons newer patient cohorts are staying on therapy longer than those who started in 2021.
The Support Vacuum
The quietest driver may be the most consequential: many patients simply never hear from anyone after the prescription is written. Obesity is a chronic, relapsing condition, yet a substantial share of real-world patients receive their prescription through a brief encounter and are left to navigate side effects, plateaus, refill logistics, and motivation on their own. Trial participants had scheduled check-ins, protocol-driven adjustments, and a team monitoring their progress. Real-world patients frequently have a pharmacy text message.
What the Data Says Improves Persistence
If the discontinuation drivers are cost, side effects, access, and isolation, the persistence levers are the mirror image, and the strongest of them is continuous clinical contact. The same JMCP analysis that documented improving persistence credited structured care management, proactive side-effect handling, and disciplined ramp-up protocols as contributing factors. Patients who have a clinician to call when nausea hits in week three are positioned to adjust rather than quit. Patients whose program monitors refill timing can catch a lapse before it hardens into discontinuation.
This is the logic behind the medically supervised telehealth model that has grown up around these therapies. TrimRx, a US telehealth platform offering online weight-loss programs built around GLP-1 medication, pairs patients with licensed providers who handle the initial clinical assessment and then remain involved through ongoing follow-up, so that the ramp-up period, side-effect questions, and progress reviews happen inside a continuous clinical relationship rather than in the silence between annual appointments. The design reflects what the persistence data keeps suggesting: personalized, supervised programs can help patients stay the course precisely because someone is watching the course.
Structure appears to matter as much as access. Programs that combine medication with lifestyle counseling, regular touchpoints, and clinician-managed adjustments are the environments in which real-world behavior starts to resemble trial behavior. None of this removes the need for individual medical judgment; these medications are not appropriate for everyone, and anyone considering them should consult a licensed healthcare provider about their own history and goals. But for appropriate candidates, the evidence increasingly indicates that the delivery model around the medication can influence outcomes as much as the molecule itself.
Where Adherence Goes From Here
Several forces now converging may reshape the persistence picture over the next few years. Oral formulations in late-stage development could remove the injection barrier that deters a segment of patients. Manufacturer price adjustments and direct-purchase programs are beginning to chip at the cost wall, and employer coverage, while still uneven, is broadening as long-term health-economics data accumulates.
The research frontier is also shifting from initiation to maintenance. A Cleveland Clinic study published in 2026 followed nearly 8,000 adults after they stopped GLP-1 therapy and found that 45 percent kept the weight off a year later, with real-world regain notably less rapid than trial-based discontinuation data had suggested, particularly among patients who transitioned into other forms of clinical and lifestyle support. That finding hints at a more sophisticated future: therapy durations tailored to the individual, structured off-ramps, and maintenance strategies that approach discontinuation as a managed clinical transition rather than a silent lapse.
Payers, meanwhile, are learning that a prescription abandoned in month two may be the most expensive kind, incurring cost without producing durable benefit. Expect adherence metrics, not just prescription volume, to become the currency by which obesity-care programs are judged.
The Variable That Decides the Outcome
The anti-obesity medication era has proven that pharmacology can move numbers on a scale. What it has not yet proven, at population level, is that health systems can keep patients connected to these therapies long enough for the science to do its work. The datasets are unambiguous: most real-world patients currently stop early, and the gap between trial outcomes and everyday outcomes is largely a persistence gap, not a potency gap.
Closing it will not require a better molecule. It will require cheaper access, faster side-effect support, uninterrupted supply, and above all, care models in which patients are accompanied rather than merely prescribed. Weight loss medication adherence rarely makes headlines, but it is the quiet variable deciding whether this generation of medicine delivers its full potential for the people who need it most.
